LD-2 disclosure · 2nd Quarter - Report
SAVE RARE TREATMENTS TASK FORCE
Client
- Description
- Dedicated to restoring the spirit of R&D incentives in the Orphan Drug Act.
- Location
- District of Columbia · United States of America
Registrant
- Description
- Consulting.
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
1 issueHealth Issues
Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases. Reauthorization of the Pediatric Rare Disease Priority Review Voucher Program. Most Favored Nation (MFN) models and international reference pricing, including GLOBE and GUARD
LobbyistsROBERT CLAYTON ALSPACH · JOSH TRENT · mrs SHANNON ROHN DEERE · NOOR AHMAD
Covered position (ROBERT CLAYTON ALSPACH): Chief Health Counsel for Chairman - House E&C Committee (E&C);Counsel - E&C, Clerk - E&C, and Paid Intern - E&C
Covered position (JOSH TRENT): Chief Health Counsel for Chairman - House E&C Committee (E&C); Deputy Chief Health Counsel - E&C; Professional Staff - E&C; Health Care Policy Advisor - Senate; Deputy Director Office of Refugee Resettlement HHS; WH Office of Presidential Personnel
TargetedSENATE · HOUSE OF REPRESENTATIVES